{"nctId":"NCT00554853","briefTitle":"PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease","startDateStruct":{"date":"2007-11"},"conditions":["Rheumatoid Arthritis"],"count":143,"armGroups":[{"label":"Pioglitazone then placebo","type":"OTHER","interventionNames":["Drug: pioglitazone","Drug: Sublingual nitroglycerine"]},{"label":"placebo then study drug (pioglitazone)","type":"OTHER","interventionNames":["Drug: pioglitazone","Drug: Sublingual nitroglycerine"]}],"interventions":[{"name":"pioglitazone","otherNames":["Actos"]},{"name":"Sublingual nitroglycerine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women on adequate contraception if they are of child-bearing age.\n* Meet revised ACR criteria for RA.\n* Stable doses of DMARDS,biologic agents and or corticosteroids for at least 3 months.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Current smokers or individuals who smoked in the last 6 months.\n* Diagnosis of Diabetes, heart failure, or infection.\n* Current diagnosis of malignant disease except for basal cell or squamous cell carcinoma of the skin.\n* No active liver disease.\n* No cholesterol-lowering medications or oral hypoglycemic agents.","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Brachial Artery Diameter Change From Baseline in Response to Reactive Hyperemia","description":"This measure represents the percentage change in diameter of brachial artery in response to reactive hyperemia. The data is presented intentionally and only for the results at the conclusion of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"9.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Rheumatoid Arthritis Disease Activity","description":"Quantification of disease activity using validated assessments (disease activity score on 28 joints (DAS28) and and C-reactive protein ( CRP) (Inflammatory marker) as a combined score (DAS-28CRP)).\n\nMean decrease in DAS-28-CRP score when compared to baseline was measured. The range of DAS-28-CRP is 0-10, with 0 meaning no active disease detected and 10 being the most severe active disease detected by joint count and C-reactive protein levels in blood.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"1.2"},{"groupId":"OG001","value":".31","spread":"1.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":72},"commonTop":["Headaches","Edema in the Ankles","Swelling to hands, feet, knees, or legs","Weight Gain","Elevated Liver Enzymes"]}}}